Objective: Hereditary breast and ovarian cancer syndrome (HBOC) increases the risk of developing breast, ovarian, prostate, and pancreatic cancers. With the insurance coverage for BRCA genetic testing, the number of individuals diagnosed with HBOC has increased. To use these test results effectively, cascade genetic testing (CGT) is recommended for at-risk relatives; however, it is not yet widely available. The purpose of this study was to investigate the willingness of the general population to share genetic test results and undergo CGT, as well as to analyze the factors influencing these decisions. Based on these findings, the study aimed to identify the types of support needed to support the sharing of genetic test results and promote the use of CGT. Methods: An online survey was conducted with 500 participants (50 men and women from each of the five generations, ranging from 20 to 69 years). Results: Among the HBOC blood relatives, 51.2% wanted to share the genetic results and 71.9% expressed a willingness to undergo CGT. “Matters to be shared with relatives” and “Helpful for my cancer prevention” were identified as key factors promoting the willingness to share the BRCA genetic test results and undergo CGT. The motivation for “Helpful for my cancer prevention” had a particularly strong influence on the decision to undergo CGT. Conclusion: In the general population, there is an emerging understanding that the genetic information impacts not only the individuals but also their entire families and can be valuable for cancer prevention. To promote the sharing of BRCA genetic test results and CGT uptake, the healthcare providers should offer support tailored to each family’s circumstances and establish cancer prevention measures recommended for HBOC.
References
[1]
Petrucelli, N., Daly, M.B. and Pal, T. (2023) Gene Reviews. BRCA1 and BRCA2 Associated Hereditary Breast and Ovarian Cancer. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK1247/
[2]
Momozawa, Y., Sasai, R., Usui, Y., Shiraishi, K., Iwasaki, Y., Taniyama, Y., et al. (2022) Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants. JAMAOncology, 8, 871-878. https://doi.org/10.1001/jamaoncol.2022.0476
[3]
Enomoto, T., Aoki, D., Hattori, K., Jinushi, M., Kigawa, J., Takeshima, N., et al. (2019) The First Japanese Nationwide Multicenter Study of BRCA Mutation Testing in Ovarian Cancer: Characterizing the Cross-Sectional Approach to Ovarian Cancer Genetic Testing of BRCA (CHARLOTTE). InternationalJournalofGynecologicCancer, 29, 1043-1049. https://doi.org/10.1136/ijgc-2019-000384
[4]
Government of Japan, Ministry of Health, Labour and Welfare. https://www.mhlw.go.jp/index.html
[5]
Barnoy, S., Dagan, E., Kim, S., Caiata-Zufferey, M. and Katapodi, M.C. (2023) Privacy and Utility of Genetic Testing in Families with Hereditary Cancer Syndromes Living in Three Countries: The International Cascade Genetic Screening Experience. FrontiersinGenetics, 14, Article 1109431. https://doi.org/10.3389/fgene.2023.1109431
[6]
Japan Organization of Hereditary Breast and Ovarian Cancer. https://johboc.jp/guidebook_g2022/q8/
[7]
Fehniger, J., Lin, F., Beattie, M.S., Joseph, G. and Kaplan, C. (2013) Family Communication of BRCA1/2 Results and Family Uptake of BRCA1/2 Testing in a Diverse Population of BRCA1/2 Carriers. JournalofGeneticCounseling, 22, 603-612. https://doi.org/10.1007/s10897-013-9592-4
[8]
Chin, T., Tan, S., Lim, S., Iau, P., Yong, W., Wong, S., et al. (2005) Acceptance, Motivators, and Barriers in Attending Breast Cancer Genetic Counseling in Asians. Cancer Detection and Prevention, 29, 412-418. https://doi.org/10.1016/j.cdp.2005.06.009
[9]
Lee, D.S.C., Meiser, B., Mariapun, S., Hassan, T., Yip, C., Mohd Taib, N.A., et al. (2020) Communication about Positive BRCA1 and BRCA2 Genetic Test Results and Uptake of Testing in Relatives in a Diverse Asian Setting. JournalofGeneticCounseling, 30, 720-729. https://doi.org/10.1002/jgc4.1360
[10]
Finlay, E., Stopfer, J.E., Burlingame, E., Evans, K.G., Nathanson, K.L., Weber, B.L., et al. (2008) Factors Determining Dissemination of Results and Uptake of Genetic Testing in Families with Known BRCA1/2 Mutations. GeneticTesting, 12, 81-91. https://doi.org/10.1089/gte.2007.0037
[11]
MacDonald, D.J., Sarna, L., van Servellen, G., Bastani, R., Giger, J.N. and Weitzel, J.N. (2007) Selection of Family Members for Communication of Cancer Risk and Barriers to This Communication before and after Genetic Cancer Risk Assessment. GeneticsinMedicine, 9, 275-282. https://doi.org/10.1097/gim.0b013e31804ec075
[12]
Ahsan, M.D., Levi, S.R., Webster, E.M., Bergeron, H., Lin, J., Narayan, P., et al. (2023) Do People with Hereditary Cancer Syndromes Inform Their At-Risk Relatives? A Systematic Review and Meta-Analysis. PECInnovation, 2, Article ID: 100138. https://doi.org/10.1016/j.pecinn.2023.100138
[13]
Afaya, A., Kim, S., Park, H.S., Lim, M.C., Jung, M.S., Nam, E.J., et al. (2024) Psychosocial Barriers and Facilitators for Cascade Genetic Testing in Hereditary Breast and Ovarian Cancer: A Scoping Review. FamilialCancer, 23, 121-132. https://doi.org/10.1007/s10689-024-00379-y
[14]
Lerman, C. (1996) BRCA1 Testing in Families with Hereditary Breast-Ovarian Cancer: A Prospective Study of Patient Decision Making and Outcomes. JAMA, 275, 1885-1892. https://doi.org/10.1001/jama.1996.03530480027036
[15]
Terui-Kohbata, H., Egawa, M., Yura, K. and Yoshida, M. (2020) Knowledge and Attitude of Hereditary Breast Cancer among Japanese University Female Students. JournalofHumanGenetics, 65, 591-599. https://doi.org/10.1038/s10038-020-0743-9
[16]
Chu, A.T., Tse, D.M., Suen, D.T.K. and Kwong, A. (2021) Baseline Knowledge and Receptiveness to Genetic Testing for Hereditary Breast and Ovarian Cancer Syndromes in Chinese High-Risk Females. JournalofCommunityGenetics, 12, 431-438. https://doi.org/10.1007/s12687-021-00518-3
[17]
Kanda, Y. (2012) Investigation of the Freely Available Easy-to-Use Software ‘EZR’ for Medical Statistics. BoneMarrowTransplantation, 48, 452-458. https://doi.org/10.1038/bmt.2012.244
[18]
Nakagomi, H., Sakamoto, I., Hirotsu, Y., Amemiya, K., Mochizuki, H., Inoue, M., et al. (2015) Willingness of Japanese Patients with Breast Cancer to Have Genetic Testing of BRCA without Burden of Expenses. BreastCancer, 23, 649-653. https://doi.org/10.1007/s12282-015-0618-7
[19]
Chu, A.T., Tse, D.M., Suen, D.T.K. and Kwong, A. (2021) Baseline Knowledge and Receptiveness to Genetic Testing for Hereditary Breast and Ovarian Cancer Syndromes in Chinese High-Risk Females. JournalofCommunityGenetics, 12, 431-438. https://doi.org/10.1007/s12687-021-00518-3
[20]
Government of Japan, Ministry of Justice. https://www.japaneselawtranslation.go.jp/en/laws/view/4275
[21]
Government of Japan, Gender Equality Bureau Cabinet Office. https://www.gender.go.jp/about_danjo/whitepaper/r04/zentai/pdf/r04_tokusyu.pdf
[22]
Muto, K., Nagai, A., Ri, I., Takashima, K. and Yoshida, S. (2023) Is Legislation to Prevent Genetic Discrimination Necessary in Japan? An Overview of the Current Policies and Public Attitudes. JournalofHumanGenetics, 68, 579-585. https://doi.org/10.1038/s10038-023-01163-z
[23]
Terui-Kohbata, H., Yotsumoto, J., Aoki, M., Oishi, Y., Uchida, N., Akagi, K., et al. (2017) Barriers to Genetic Counseling of Hereditary Breast and Ovarian Cancer in Japan. IryotoShakai, 27, 261-275. https://doi.org/10.4091/iken.2017.003
[24]
The National Cancer Center Japan. https://ganjoho.jp/reg_stat/statistics/stat/screening/screening.html
[25]
(2022) OECD Health Statistics. https://www.oecd.org/en/data/datasets/oecd-health-statistics.html
[26]
Nakama, M., Matsuyama, H., Murase, S., Asano, Y., Nimura, M., Iinuma, K., et al. (2022) A Survey of Clinical Management for HBOC in Japan. Journal of Hereditary Tumors, 22, 1-8.
[27]
Lee, D.S.C., Meiser, B.M., Mariapun, S. et al. (2021) Communication about Positive BRCA1 and BRCA2 Genetic Test Results and Uptake of Testing in Relatives in a Diverse Asian Setting. Journal of Genetic Counseling, 30, 720-729. https://doi.org/10.1002/jgc4.1360
